Blog post amended to correctly characterize Aspen's Vivus ownership stake.
Aspen Investments and Zoi Potsi, a resident of Cyprus, declared a 9.65% ownership stake in struggling obesity pill marketer Vivus (VVUS - Get Report) this morning and say they want to buy the rest of the company for $640 million.
Interesting takeout offer, but is it serious? Vivus shares are up just 4% to $4.87 after Aspen's 13-D SEC filing was reported.
Aspen Investment is a limited liability corporation registered in Delaware on May 16, 2014. Aspen's registered address appears to be a blue house situated against a marsh near the Delaware coastline.
Zoe Potsi might be a lawyer living in Cyprus, according to this LinkedIn profile. She appears to work for this law firm.
According to the 13-D filed today, Aspen Investments owns 9.96 million shares of Vivus, or 9.65% of the company, sort of. The filing says a majority of Aspen's Vivus stake is in forward purchase contracts and not actual company shares. Aspen began buying a stake in Vivus on May 16 at $4.88 per share and continued buying through May 23 at $4.62 per share. Aspen also owns Vivus options.
As for the takeover offer, here's what Aspen says in the filing:
Aspen Investment Fund is currently contemplating a conditional non-binding offer to acquire the Issuer at a total consideration of $640 million, which would be financed using Aspen Investment Fund working capital, Issuers cash & cash equivalents and debt from top tier investment banks. The conditional non-binding offer should be submitted to the board by June 13, 2014. Although Aspen Investment Fund currently expects to make an offer, it is under no obligation and provides no assurances it will do so, if there are any material changes to the Issuers operations, financial situation or enterprise value.
05/19/15 - 04:42 PM EDT
05/19/15 - 12:48 PM EDT
05/18/15 - 08:06 AM EDT
05/05/15 - 02:43 PM EDT
05/05/15 - 10:40 AM EDT
09/02/15 - 08:59 AM EDT
09/01/15 - 08:32 AM EDT
08/31/15 - 01:03 AM EDT
08/31/15 - 01:01 AM EDT
08/31/15 - 01:00 AM EDT
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.